Cardior Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Cardior Pharmaceuticals's estimated annual revenue is currently $6.8M per year.
- Cardior Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Cardior Pharmaceuticals has 44 Employees.
- Cardior Pharmaceuticals grew their employee count by 10% last year.
Cardior Pharmaceuticals's People
Name | Title | Email/Phone |
---|
Cardior Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Cardior Pharmaceuticals?
Cardior is an academic spin-off from Medical School Hannover (MHH). Founded in 2016, a Series A financing round of 15 mn. EUR was successfully closed in May 2017. The company is focused on the development and clinical validation of noncoding (ncRNA) RNA therapeutics for patients with myocardial infarction and heart failure.
keywords:N/AN/A
Total Funding
44
Number of Employees
$6.8M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cardior Pharmaceuticals News
2022-04-06 - Movers & Shakers, April 8 | BioSpace
Cardior Pharmaceuticals: Russel Grieg was named independent chairman of the board of directors at Cardior. Greig brings more than 35 years...
2022-04-06 - Cardior Appoints Dr. Russell Greig as Independent Chairman of the ...
HANOVER, Germany--(BUSINESS WIRE)--Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 44 | 10% | N/A |
#2 | $11.6M | 44 | 5% | N/A |
#3 | $10.8M | 44 | -8% | N/A |
#4 | $6.3M | 45 | -8% | N/A |
#5 | $3.7M | 46 | -8% | N/A |